Explanation: Awiqli (insulin icodec) is the world’s first and only once-weekly basal insulin approved for clinical use in adults with Type 1 and Type 2 Diabetes Mellitus, providing background glycaemic control for up to seven days. Developed by Novo Nordisk, India has become the seventh market globally to launch this drug.

Source- ddnews